Close Menu

CHARLOTTE, North Carolina (GenomeWeb) – At the Association for Molecular Pathology here this week, Thermo Fisher Scientific announced a new research panel for profiling gene expression in tumors and their surrounding microenvironment, which it hopes has the potential to predict response to cancer immunotherapies with more sensitivity than current assays.

The new offering, called the Oncomine Immune Response Research Assay, enables targeted sequencing of 396 gene transcripts using Ion Torrent next-generation sequencing platforms, with low sample input requirements.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.